Botulinum toxin type A is under clinical development by Microgen and currently in Phase III for Migraine. According to GlobalData, Phase III drugs for Migraine have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Botulinum toxin type A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Botulinum toxin type A overview
Botulinum toxin A (Relatox) is a neuromuscular blocking agent which is produced from fermentation of hall strain clostridium botulinum type A. It is formulated as powder for solution for intramuscular route of administration. Relatox is indicated for the treatment of blepharospasm and correction of hyperkinetic facial wrinkles (expression lines) in adults.
Botulinum toxin A (Relatox) is also under development for the treatment of migraine and spasmodic torticollis (cervical dystonia).
Botulinum toxin A (Relatox) was also under development for the treatment of overactive bladder, neurogenic bladder dysfunction and upper limb muscle spasticity.
Microgen is a manufacturer of immunobiological products and engaged in production of vaccines for the treatment of infectious diseases. Microgen is headquartered in Moscow, Russia.
For a complete picture of Botulinum toxin type A’s drug-specific PTSR and LoA scores, buy the report here.